Statins and LDL-C in Secondary Prevention—So Much Progress, So Far to Go
Open accessAbstract
Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Statins are effective, safe, and affordable but fail to meet LDL-C goals or are poorly tolerated by some patients.
“The primary choice of statins works well due to their effectiveness and safety as well as affordability, but they fail to meet LDL-C goals or are poorly tolerated by patients [74–76].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 10 · Cited by 45
Research works printed but not linked: 5
- Penson PE, Pirro M, Banach M. LDL-C: lower is better for longer-even at low risk. BMC Med. 2020;18(1):320. doi:10.1186/s12916-020-01792-7 · DOI
- Mach F, Baigent C, Catapano AL, et al; ESC Scientific Document Group. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455 · DOI · Paper page
- Ray KK, Molemans B, Schoonen, WM, et al EU-Wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. Published online August 28, 2020. doi:10.1093/eurjpc/zwaa047 · DOI · Paper page
- Banach M, Penson PE. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER? Cardiovasc Res. 2019;115(3):e26-e31. doi:10.1093/cvr/cvy301 · DOI
- Solnica B, Sygitowicz G, Sitkiewicz D, et al. 2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders. Arch Med Sci. 2020;16(2):237-252. doi:10.5114/aoms.2020.93253 · DOI
- Authors
- Banach, M., & Penson, P. E.
- Affiliations
- Medical University of Lodz (PL)
- Liverpool John Moores University (GB)
- Corresponding author
- Banach, Maciej
- Venue
- JAMA Network Open
- Publisher
- American Medical Association (AMA)
- Published
- 2020-11-20
- Volume
- 3
- Issue
- 11
- Pages
- e2025675
- ISSN
- 2574-3805 (ISSN-L)
- OpenAlex
- W3103733434
- Cited by
- 45
- References
- 10
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 6 · 2023: 5 · 2022: 5 · 2021: 16 · 2020: 1
- FWCI
- 6.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- JAMA Network Open (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Liverpool John Moores University (submittedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- statins, LDL cholesterol, secondary prevention, atherosclerotic cardiovascular disease, lipid-lowering therapy
- MeSH terms
- Adult, Cardiovascular Diseases, Humans, Cholesterol, LDL, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
